Cell-based flu vax listed on NIP

	Rachel Fieldhouse A CELL-based quadrivalent flu	conditions , can get CSL Seqirus ’ Flucelvax Quad for free .	vulnerable Australians are not getting vaccinated .”		They demonstrated that Flucelvax Quad was non-inferior
	vaccine will be available on the	Infectious diseases paediatri-	Flucelvax Quad was first made	for protecting against A ( H1N1 ),
	National Immunisation Program for	cian Professor Robert Booy , from	available in 2021 on a private script	A ( H3N2 ), B / Victoria and B /
	the first time this year for patients	the University of Sydney , said the	for patients aged nine or older , with	Yamagata strains .
	at higher risk of complications from	listing gave GPs and patients “ an	eligibility expanding to include	Separately , a 2023 systematic
	influenza .	important option for protection ”	children aged six months or older in	review and meta-analysis showed
	From 1 March , Aboriginal and	given suboptimal uptake of the flu	July last year .	that cell-based quadrivalent flu
	Torres Strait Islander people aged	shot last year .	The change was based on results	vaccines were “ significantly more
	5-64 ; pregnant women ; and patients	“ In 2023 , approximately 25 % of	from three studies involving chil-	effective at reducing medical
	aged 5-64 with co-existing condi-	the population aged 5-64 were vac-	dren , two of which compared the	encounters ” in patients aged 4-64
The vaccine is for those at high risk of complications .	tions , including diabetes , chronic renal failure , heart disease and chronic respiratory or neurological	cinated against influenza ,” he said . “ With coverage like that , there is certainly a strong chance that many	immune response from Flucelvax Quad to that derived from a comparator trivalent or quadrivalent vaccine .	compared with traditional eggbased vaccines . Vaccines ( Basel ) 2023 ; 17 Oct .

† 3,4

LOWEST LDL-C IS BEST * 1 , 2

Learn more at beyondstatins . com . au

* There is a linear association between lower LDL-C and lower CV risk in secondary prevention studies , with no lower limit for the association ( or ‘ J-curve ’ effect ). 1 , 2

Fighting injustice

FROM PAGE 1 critiquing the footpaths and pedestrian crossings .

Later , a 40-page submission to Adelaide Airport got him a meeting with senior management , where he secured an airport upgrade , including a toileting spot for guide dogs .

Today , Dr Squirrell continues his fight for social justice . His particular bugbear are the rules allowing cyclists and e-scooters on footpaths .

“ I ’ ve been bowled over four times by cyclists — not one has stopped , apologised and helped me up ,” he says .

He also talks about the violence people with disability face . He says he has been mugged and threatened in public .

“ They think it ’ s funny to attack someone who cannot identify them .”

While his calling to medicine came early at the age of

Dr David Squirrell with dog

Viking .

PREVENT

†

ANOTHER CV EVENT † 3 , 4

Repatha ® is indicated for the prevention of CV events ( MI , stroke and coronary revascularisation ) in adults with established CV disease in combination with an optimally dosed statin and / or other lipid-lowering therapies , as an adjunct to diet and exercise . 3

‘ Power ’: 15 % relative risk reduction with Repatha ® vs placebo in the composite of the primary endpoint beyond optimised statin ± ezetimibe ( HR : 0.85 ; 95 % CI : 0.79 – 0.92 , p < 0.001 ). 4

PBS Information : Authority Required . Non-familial and familial hypercholesterolaemia . Criteria apply for certain patient populations . Refer to PBS Schedule for full Authority Required Information .

Refer to full Product Information before prescribing ; available from Amgen Australia Pty Ltd , Ph : 1800 803 638 or by scanning the QR code : For more information on Repatha ® or to report an adverse event or product complaint involving Repatha ® , please contact Amgen Medical Information on 1800 803 638 or visit www . amgenmedinfo . com . au .

Precautions : Hypersensitivity reactions . Concomitant lipid lowering therapies – check all relevant prescribing information . Effects of long-term very low LDL-C levels are unknown . Immunogenic potential . Pregnancy Category : B1 . Caution – breastfeeding . Adverse Reactions : Common – nasopharyngitis , upper respiratory tract infection , influenza , back pain , arthralgia , nausea , rash , and injection site reactions ( including injection site pain , erythema , bruising , swelling or haemorrhage ).

Abbreviations : CI , confidence interval ; CV , cardiovascular ; HR , hazard ratio ; LDL-C , low-density lipoprotein cholesterol ; MI , myocardial infarction ; PBS , Pharmaceutical Benefits Scheme .

References : 1 . Mach F , et al . Eur Heart J 2020 ; 41 ( 1 ): 111 – 188 . 2 . Packard C , et al . Heart 2021 ; 107:1369 – 1375 . 3 . Repatha ® ( evolocumab ) product information . 4 . Sabatine MS , et al . N Engl J Med 2017 ; 376:1713 – 1722 .

13 , five years later he underwent major surgery for bifid ureters , grade 4 reflux with chronic pyelonephritis and associated renal hypertension and intermittent renal haemorrhage . And he says it was the experience that shaped him .

“ I understood what it was to be vulnerable and the need to have someone who would stand up and fight for you .” Does he miss being a doctor ?

“ Yes ,” he says . “ You have the chance to make a real difference to people ’ s lives .”

Last month , Dr Squirrell was awarded an OAM for his service to people with disability .

AMG8657 _ Repatha Print Media 24 _ Aus Doc _ A4 _ 210x273 _( MALE )_ V0.4 _ FA . indd 1 5 / 2 / 2024 3:31 pm

Australian Doctor 16th February 2024 AD 16th Feb issue | Page 4

4 NEWS

4 NEWS

Cell-based flu vax listed on NIP

Fighting injustice

PREVENT

ANOTHER CV EVENT † 3 , 4